Tamilvanan Shunmugaperumal

Prof. Dr. Tamilvanan Shunmugaperumal

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Journal of Controlled Release
Verified
Journal Article
Closed access
TSTamilvanan Shunmugaperumal
Tamilvanan Shunmugaperumal
NVNarayanan Venkateshan
Narayanan Venkateshan
ALAnnick Ludwig
Annick Ludwig


1 March 2010 in Journal of Drug Targeting
Verified
Journal Article
Closed access
PDF file
TSTamilvanan Shunmugaperumal
Tamilvanan Shunmugaperumal
NRNatarajan Livingston Raja
Natarajan Livingston Raja
BSBiswanath Sa
Biswanath Sa
SBSanat Kumar Basu
Sanat Kumar Basu
Similar to the low molecular weight traditional drugs, biopharmaceuticals are capable of producing not only therapeutic effects but also side effects provided if the dose of these compounds exceeds certain concentration and/or if the exposure duration of these compounds at subtoxic doses is being lengthened. In addition, a major drawback of biopharmaceuticals is the risk of antibody formation. Following the administration of biopharmaceuticals into human body, the formation of antidrug–antibody (ADA) or neutralizing antibody and other general immune system effects (including allergy, anaphylaxis, or serum sickness) are of clinical concern regarding therapeutic efficacy and patient safety. For example, drug-induced neutralizing antibodies to erythropoietin (EPO) result in pure red cell aplasia, whereas drug-induced acquired anti-factor VIII antibodies worsen the pathology associated with hemophilia. Since most of the already developed or under development biopharmaceuticals are to some extent immunogenic, the regulatory agencies insist to conduct potential ADA formation during the drug development process itself. This review encompasses a short overview on the clinical concerns of immunogenicity produced at cellular levels by growth hormone, interferon-α, EPO, factor VIII, and factor IX following their parenteral administration into human body. Clinical concerns related to immunogenicity produced by the biosimilar versions of these drugs are also presented wherever possible.

29 June 2010
Verified
Book
Open access
TSTamilvanan Shunmugaperumal
Tamilvanan Shunmugaperumal
Click on the title to browse this book

1 July 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
TSThenrajan Raja Sekharan
Thenrajan Raja Sekharan
OKOly Katari
Oly Katari
SRSyed Nazrin Ruhina Rahman
Syed Nazrin Ruhina Rahman
DPDatta Maroti Pawde
Datta Maroti Pawde
AGAbhinab Goswami
Abhinab Goswami
TSTamilvanan Shunmugaperumal
Tamilvanan Shunmugaperumal

13 May 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
SRSyed Nazrin Ruhina Rahman
Syed Nazrin Ruhina Rahman
OKOly Katari
Oly Katari
DPDatta Maroti Pawde
Datta Maroti Pawde
GBGopi Sumanth Bhaskar Boddeda
Gopi Sumanth Bhaskar Boddeda
AGAbhinab Goswami
Abhinab Goswami
TSTamilvanan Shunmugaperumal
Tamilvanan Shunmugaperumal